The ‘best’ vaccine: how does Pfizer fare against the others?
The brand approved for emergency use in SA wins for efficacy but loses for its dosing regimen
The Pfizer-BioNTech vaccine, approved for emergency use this week by the SA Health Products Regulatory Authority, has some advantages over other Covid-19 vaccines already here or due to arrive. But it’s not a clear winner in all categories and comes last in some.
According to a new study, carried out by Novateur Ventures, a Canadian Covid-19 resource centre, and led by Queen’s University, the Pfizer-BioNtech vaccine tops the charts alongside Moderna when it comes to efficacy.
The researchers carried out a comparative analysis of 12 vaccines that had already initiated or announced their phase three clinical trials by early November last year...